Formation Bio raises $600M fund to scale AI-powered drug development
a16z · x · 2026-10-28
Formation Bio announced a $600M Drug Development Accelerator Fund, arguing the real bottleneck in bringing medicines to patients has shifted from discovery to development. As AI dramatically speeds up discovery, capital, experienced teams and clinical capacity are becoming scarcer. The fund pairs dedicated capital with Formation Bio's drug developers and AI platform to acquire promising drugs and advance them through clinical trials across a larger portfolio.
More from AGI Musings
- ML researcher: discipline yourself to think before asking the AI oracle — johnowhitaker · 2026-10-28
- Johns Hopkins lands up to $52M from ARPA-H to build AI that decodes protein misfolding — JosephJacks_ · 2026-10-28
- Everpure CEO: messy enterprise data blocks AI's trillion-dollar automation promise — TiernanRayTech · 2026-10-28
- Google AI's Pilar Manchón on AI for cancer detection, crystal discovery and dolphin communication — pilarmanchon · 2026-10-28
- Echoes of 1999: fiber glut left 97% unused, but hoarded $30k AI chips won't flood the market — aakashgupta · 2026-10-28
- Stanford prof: LLM reviewers catch mistakes scientists keep missing — anshulkundaje · 2026-10-28